Navigation Links
Non-melanoma skin cancer may help identify survivors at increased risk for future cancers
Date:6/7/2010

Childhood cancer survivors diagnosed later with non-melanoma skin cancer may be at increased risk for having a malignant tumor within 15 years, according to research led by St. Jude Children's Research Hospital investigators.

Almost 20 percent of survivors in this Childhood Cancer Survivor Study (CCSS) who were diagnosed with basal or squamous cell skin cancer developed another more aggressive cancer within 15 years, said Gregory Armstrong, M.D., assistant member of the St. Jude Department of Epidemiology and Cancer Control. He presented the results June 7 at the 46th Annual Meeting of the American Society of Clinical Oncology in Chicago.

"These findings suggest non-melanoma skin cancers are a potential marker for survivors who are at risk for future invasive malignancies," Armstrong said.

The study involved 14,358 childhood cancer survivors whose cancer was diagnosed between 1970 and 1986. All are now participating in the CCSS, which is funded by the National Cancer Institute to track the health outcomes of childhood cancer survivors. Armstrong is project director for CCSS, which includes investigators at 30 institutions in the U.S. and Canada. St. Jude is the central coordinating institution. Les Robison, Ph.D., St. Jude Epidemiology and Cancer Control chair, is the CCSS principal investigator. He is also this study's senior author.

Childhood cancer survivors are known to be at increased risk for additional cancers, which remain a leading cause of disability and death among those who beat cancer the first time. "This study is the first to track the risk of multiple malignancies in a large group of aging cancer survivors," Armstrong said. The average survivor in this study was age 36.

Nearly 10 percent of study participants, or 1,383 survivors, reported being diagnosed with a second tumor. The group included 231 survivors found to have a third tumor and 153 individuals diagnosed with four or more. The analysis found that nearly 39 percent of childhood survivors diagnosed with one subsequent tumor went on to develop another within 15 years.


'/>"/>

Contact: Summer Freeman
summer.freeman@stjude.org
901-297-9861
St. Jude Children's Research Hospital
Source:Eurekalert

Related medicine news :

1. Non-Melanoma Skin Cancers in the Millions and Rising
2. Consortium seeks best treatment for HIV-positive cancer patients
3. Drug that helps metastatic colon cancer of no benefit in less advanced tumors
4. B2Discovery: Entrepreneurs and researchers join forces to conquer cancer
5. ASCO data show serum DNA blood tests detect cancers with high sensitivity and specificity
6. Molecular imaging detects recurrent prostate cancer
7. New treatment regimen shown effective against advanced ovarian cancer
8. Targeted Therapy Shows Promise Against Deadly Brain Cancer
9. Less-invasive Lymph Node Resection Following Breast Cancer Surgery Confirmed as Standard of Care in Eight-year Study Led by AGH Doctors
10. Researchers Report Treatment Headway Against Lung Cancer
11. Selenium shows no benefit in prevention of lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... ... 27, 2017 , ... For bicycling enthusiasts around the globe, Germany's famous Rad ... place against a backdrop of tree-lined hills at the Nürburgring, a Formula One arena ... am Ring consists of some 73 curves, stretching out over more than 500 meters ...
(Date:7/27/2017)... ... July 27, 2017 , ... ... secure cloud-based polysomnography (PSG) distributed scoring solution to its healthcare management platform. This ... care management. The speed and functionality of scoring in the cloud is on ...
(Date:7/27/2017)... Plano, TX (PRWEB) , ... July 27, 2017 ... ... technology and outsourced services, announces the internal promotion of Elrene Clinkscales to Vice ... Operations – Claims & Remittance Management, reporting to Derek Morkel, chief executive officer ...
(Date:7/27/2017)... , ... July 27, 2017 , ... ... as a finalist in this year’s Fierce Innovation Awards: Healthcare Edition 2017, an ... finalist in the category of Population Health Management/Patient Engagement Solutions. , MAP ...
(Date:7/27/2017)... ... , ... Cremations recently surpassed traditional burials for the first time in the ... continue with over 70% of Americans projected to choose cremation by 2030. , In ... families to celebrate the life of a lost loved one in different ways using ...
Breaking Medicine News(10 mins):
(Date:7/26/2017)... Sancilio Pharmaceuticals Company, Inc. (SPCI) today announced ... Altemia TM , an oral therapy for pediatric patients ... (SCD). The SCOT Trial, is a double-blind, placebo-controlled, dose-finding, ... Altemia TM in pediatric patients aged 5-17 years ... "The completion of ...
(Date:7/24/2017)... IBM (NYSE: IBM ) has been recognized ... Arrays (SSA) for the fourth year in a row. 1 ... "Vendors in the Leaders quadrant have the highest scores for ... in the Leaders quadrant has the market share, credibility, and ... new technologies. These vendors demonstrate a clear understanding of market ...
(Date:7/21/2017)... 21, 2017  Endo International plc (NASDAQ: ... review of its manufacturing network, the Company will be ... in Huntsville, Alabama . The closure ... the next 12 to 18 months. The ... volumes of commoditized products and these restructuring actions are ...
Breaking Medicine Technology: